MicroRNAs (miRNAs) are a recently discovered class of small, non-coding RNAs which do not code proteins. MiRNAs regulate gene expression by inhibiting protein translation from the messenger RNA. MiRNAs may function in networks, forming a complex relationship with diseases. Furthermore, specific miRNAs have significant correlation with diseases of divergent origin. After identification of disease-associated miRNAs, their tissue expression could be altered in a beneficial way by inhibiting or mimicking their effects. Thus, modifying the expression of miRNAs is a potential future gene-therapeutic tool to influence post-transcriptional regulation of multiple genes in a single therapy. In this review we introduce the biogenesis, mechanism of action and future aspects of miRNAs. Research on the post-transcriptional regulation of gene expression by miRNA may reshape our understanding of diseases and consequently may bring new diagnostic markers and therapeutic agents. Therapeutic use of miRNAs is already under clinical investigation in RNA interference trials.
Since the first description of the genetic material in 1953 by James Watson and Francis Crick (65) three discoveries honoured by a Nobel Prize have reshaped our understanding of gene-expression regulation. The "central dogma" of unidirectional genetic information flow (DNA → RNA → protein) by Francis Crick, 1958 (7) has been broken first in 1970 by David Baltimore's discovery of reverse transcriptase (54) , and than in 1982 by Stanley Prusiner's description of a proteinaceous infectious substance (prion) (47) . In 1986 Ecker and Davis described that antisense RNA can inhibit gene expression in plants (10) providing a new role for RNAs. However, the relevance of this discovery was not given wide attention until 1998 when Craig C. Mello and Andrew Fire described RNA interference (RNAi) in eukaryotes (C. elegans) (14) . This discovery of small RNAs not coding proteins opened a brand new field in biology: investigating regulatory roles of RNAs, previously thought to merely pass information from DNA to proteins.
Analysis of the human transcriptome revealed that it contains thousands of functioning RNAs that are not included in protein synthesis (non-coding RNAs) (41) . Some of these noncoding RNAs are short microRNAs (miRNAs) with gene expression regulatory function first described in 1993 (38) . Genes encoding miRNAs have been shown to make up to 1% of the genome (5). MiRNAs are short: 18-25 nucleotide (nt), double stranded RNAs (58) , and their action is achieved through RNAi, following DNA → RNA transcription (36) . Understanding the effects of miRNAs could dramatically change our schemes of gene regulation.
Controlling functions in our body form networks, in which miRNAs might play a crucial role (30) . A single miRNA can alter the expression of many messenger RNAs (mRNA), furthermore, expression of one mRNA might be under the control of several miRNAs. The disease and stage specific miRNA expression profile can be detected by multiplex methods, such as microarray or microbead hybridization methods (Luminex /Biomedica Hungaria/, Bioplex /Biorad/). Together with these methods, real time quantitative polymerase chain reaction (qPCR) might give us more precise results on individual miRNA expressions leading to a better insight into the mechanism of miRNome network. (9, 12, 20, 32, 44) Micro RNAs function by post-transcriptional gene silencing, meaning silencing the messenger RNA also called RNA interference (RNAi). Micro RNAs bind to and inhibit the translation of the complementary sequence messenger RNAs. Molecular mechanisms of RNAi were first described in detail for short interfering RNAs (siRNAs). For further information on siRNAs we refer to our recent reviews (52, 53) . Double-stranded (ds)RNA can also activate gene expression (RNAa) by targeting gene promoters thus, inducing transcriptional activation (37) .
MiRNAs are generated from endogenously transcribed, hairpin structures (5). MiRNA coding genes are transcribed by RNA polymerase II (pol II) and the transcript is named primary miRNA (pri-miRNA) (39), from which nucleotides are cleaved by Drosha (RNase enzyme) inside the nucleus. This second product is called pre-miRNAs and is recognized by nuclear export factor Exportin-5 (Exp5/Xpo5), which traffics pre-miRNAs into the cytoplasm (40) . The following steps are mediated by Dicer (RNase III enzyme): it cleaves the hairpin structure and forms the miRNA-specific ends. The outcome of this processing is a doublestranded, 18-25 nt long dsRNA, named miRNA (28) . The so-called guide (antisense) strand keeps its strong contact with the RNA-induced silencing complex (RISC), while the other strand is degraded (31) . The guide strand binds the complementary messenger RNA (mRNA), Insights into the world of microRNAs and is followed by the degradation of the complementary mRNA, a mechanism, that requires full match complementarity and predominantly occurs in plants (5) . The mechanisms of posttranscriptional gene silencing mediated by miRNAs are summarized in Table I ( Blocking the initiation of translation (on eukaryotic initiation factor, eIF)
Blocking the elongation
Degradation of newly synthesized proteins Sequestration of miRNAs (i.e. in the P-bodies) (27) Further silencing mechanisms of miRs While miRNAs in plants direct cleavage of the targeted mRNA as described above, in animals there is usually a lack of extensive complementarity required for cleavage by Argonaute proteins (29) , revealing prominent regulation at the protein level by ribosome drop off during elongation of translation (50) . Furthermore, mRNA decreases are associated with poly(A)-tail shortening, leading to mRNA de-adenylation, de-capping and consequent rapid degradation (67) . This indicates that microRNAs act as rheostats to make fine-scale adjustments of protein level (4) . Further experiments suggest that miRNAs repress translation initiation by preventing 60S ribosome subunit joining to miRNA-targeted mRNAs (63) . As to Guo and colleagues lowered mRNA levels account for most (≥84%) of the decreased protein production, indicating that mRNA destabilization plays a key role in reduced protein translation (18) . Thus, miRNA-mediated silencing manifests at both protein and mRNA levels. Although there are abundant data on the proposed model of influencing translation initiation by miRNAs (8) , further experiments are needed to reveal the mechanism of action of miRNAs in eucariots.
Nomenclature of miRNAs
The correct naming of miRNAs necessitated the establishment of a universal nomenclature of miRNAs (Table II) . There are many online data bases, which help scientists to explore the sequence of different miRNAs or the structure of their precursor pri-miRNA molecule. Other online tools may be useful in identifying possible miRNA-mRNA interactions (Table  III) (61) or endocrine mechanisms (miR-375) (51). Thus, miRNAs are associated to many physiological (5) and pathophysiological mechanisms (13) .
Altering miRNA expression in vivo
Since miRNA expression is altered in many diseases, therapeutic influence on miRNA function may be beneficial. One major problem of in vivo nucleic acid (siRNA, miRNA, antisense oligodesoxynucleotide, plasmid DNA) therapy is the delivery of the nucleic acid to target organs and into cells (49) . The issues of in vivo therapy are assessed in Table IV . 
Instability of nucleic acids in extracellular fluids
Short half-life (seconds) due to nuclease degeneration in body fluids (22) Fast filtration by the kidney (15) Low cell membrane penetration due to negative charge (52) Several methods have been investigated to support in vivo delivery of nucleotides, the main groups of which are summarized below:
Physical forces (high pressure, high volume): Local or systemic injection of nucleic acids dissolved in a large volume helps them to cross their cellular uptake (19) , since the high volume diminishes the efficacy of nucleases, while high pressure presses the nucleotides into the interstitium of parenchymal organs, and then through the cell membrane into the cytoplasm, the place of RNAi. Similar pore openings can be achieved with sonoporation (60) or electroporation (21, 66) .
Chemical modifications: Altering the structure of a nucleic acid with the aim of therapeutic application includes the modification of the ribose backbone (35) the terminals (by addition of methyl, alkyl (11) or cholesterol group (59) or synthetic molecules: non-ionic DNA analogues=morpholinos) (55) or locked nucleic acids (LNA) (62) .
Vectors, plasmid DNA (pDNA): Viral and non-viral vectors, polycations (polyplexes (57): poly-ethylene-imine (PEI) (17) , polyethylene glycol (PEG) or poly-L-lysine), complexing with molecules of lipid nature (developing liposomes with for instance Lipofectamine RNAiMax®) can enhance cellular nucleic acid uptake (68) .
Conjugation with cell surface receptor ligands: enables cell specific uptake (45) . Depo-products (carriers, such as gelatine (46) , hydrogels (33), atelocollagen (3) or citosan) can elongate silencing effect.
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Diagnostic value of miRNAs
Many disease-specific miRNA expression patterns and/or miRNA amounts could be clinically used in diagnosing and evaluating prognosis, for instance with real-time PCR (34) . Human malignant tumor-specific miRNA chips are already commercially available (48) Huang and colleagues described that the plasma level of some miRNAs (miR-29a, miR-92a) have diagnostic value in advanced colorectal cancer (26) . Other miRNAs (miR-146a, miR-223) have been shown to be significantly associated with sepsis (miR-146a, miR-223) (64) . Furthermore, miR-1 is a new biomarker of cardiac muscle ischemia, independent of many factors (age, sex, blood pressure, diabetes mellitus) (1).
Conclusions
MiRNAs play a crucial role in the development and course of diseases. Multiplex understanding of the miRNome may have diagnostic and therapeutic relevance.
